SciELO - Scientific Electronic Library Online

vol.146 número2Patrón de tabaquismo y nivel socioeconómico en dos cohortes de adultos jóvenesColitis de Crohn: resultados del tratamiento quirúrgico y evolución alejada índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados




Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google


Revista médica de Chile

versão impressa ISSN 0034-9887


LEON, Pilar et al. Acquired aplastic anemia. Experience in a public hospital. Rev. méd. Chile [online]. 2018, vol.146, n.2, pp.175-182. ISSN 0034-9887.


The first line treatment for patients < 40 years old with aplastic anemia (AA) is allogeneic HLA-identical sibling donor transplantation (SCT). Immunosuppressive therapy (IST) with a combination of Thymoglobuline (ATG) and cyclosporine is used for older patients or those without a donor. Five year overall survival (OS) for both therapies is > 70%.


To report the experience with SCT and ATG for AA in a public hospital.

Patients and Methods:

AA was diagnosed in 42 patients between 1998 and 2016, according to Camitta criteria. Thirty eight (90%) received treatment, 7 (18%) under 40 years old received SCT, and 31 (82%) IST. The rest were not treated. OS was calculated from date of diagnosis until last control, death or loss from follow up.


Complete or partial hematologic response, was obtained in 71% and 58% of cases with SCT and IS, respectively. Five year OS was 71% and 55% with SCT and IST, respectively. No difference in response was observed between horse and rabbit ATG.


SCT from an HLA-identical sibling donor had a high response rate and survival. IST instead, had a lower response and survival, due to an initial high mortality rate.

Palavras-chave : Anemia; Aplastic; Homologous; Immunosuppression; Stem Cell Transplantation; Transplantation.

        · texto em Espanhol     · Espanhol ( pdf )